Paul Sagan - Mar 3, 2025 Form 4 Insider Report for Moderna, Inc. (MRNA)

Role
Director
Signature
/s/ James Dillon, Attorney-in-Fact
Stock symbol
MRNA
Transactions as of
Mar 3, 2025
Transactions value $
$1,004,251
Form type
4
Date filed
3/4/2025, 04:24 PM
Previous filing
May 7, 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MRNA Common Stock Purchase $1M +31.6K +11.28% $31.76 312K Mar 3, 2025 By: The Paul Sagan Revocable Trust F1, F2
holding MRNA Common Stock 703 Mar 3, 2025 Direct
holding MRNA Common Stock 15K Mar 3, 2025 By: Erwin Park LLC F3
holding MRNA Common Stock 166K Mar 3, 2025 By: The Chatham Trust F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $31.46 to $31.95. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F2 This balance reflects the transfer of 90,000 shares of the Issuer's common stock from The Paul Sagan Revocable Trust to The Chatham Trust on November 21, 2024.
F3 Erwin Park LLC is an investment vehicle owned by the Reporting Person's children. The Chatham Trust is an irrevocable family trust for which the Reporting Person serves as a trustee. The Paul Sagan Revocable Trust is a revocable trust for which the Reporting Person serves as a trustee. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.